Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 2
2019 4
2020 4
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

9 results
Results by year
Filters applied: . Clear all
Page 1
K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways.
Scheffler M, Ihle MA, Hein R, Merkelbach-Bruse S, Scheel AH, Siemanowski J, Brägelmann J, Kron A, Abedpour N, Ueckeroth F, Schüller M, Koleczko S, Michels S, Fassunke J, Pasternack H, Heydt C, Serke M, Fischer R, Schulte W, Gerigk U, Nogova L, Ko YD, Abdulla DSY, Riedel R, Kambartel KO, Lorenz J, Sauerland I, Randerath W, Kaminsky B, Hagmeyer L, Grohé C, Eisert A, Frank R, Gogl L, Schaepers C, Holzem A, Hellmich M, Thomas RK, Peifer M, Sos ML, Büttner R, Wolf J. Scheffler M, et al. Among authors: abdulla dsy. J Thorac Oncol. 2019 Apr;14(4):606-616. doi: 10.1016/j.jtho.2018.12.013. Epub 2018 Dec 31. J Thorac Oncol. 2019. PMID: 30605727 Free article.
Genetic Heterogeneity of MET-Aberrant NSCLC and Its Impact on the Outcome of Immunotherapy.
Kron A, Scheffler M, Heydt C, Ruge L, Schaepers C, Eisert AK, Merkelbach-Bruse S, Riedel R, Nogova L, Fischer RN, Michels S, Abdulla DSY, Koleczko S, Fassunke J, Schultheis AM, Kron F, Ueckeroth F, Wessling G, Sueptitz J, Beckers F, Braess J, Panse J, Grohé C, Hamm M, Kabitz HJ, Kambartel K, Kaminsky B, Krueger S, Schulte C, Lorenz J, Lorenzen J, Meister W, Meyer A, Kappes J, Reinmuth N, Schaaf B, Schulte W, Serke M, Buettner R, Wolf J. Kron A, et al. Among authors: abdulla dsy. J Thorac Oncol. 2021 Apr;16(4):572-582. doi: 10.1016/j.jtho.2020.11.017. Epub 2020 Dec 9. J Thorac Oncol. 2021. PMID: 33309988
Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.
Michels S, Massutí B, Schildhaus HU, Franklin J, Sebastian M, Felip E, Grohé C, Rodriguez-Abreu D, Abdulla DSY, Bischoff H, Brandts C, Carcereny E, Corral J, Dingemans AC, Pereira E, Fassunke J, Fischer RN, Gardizi M, Heukamp L, Insa A, Kron A, Menon R, Persigehl T, Reck M, Riedel R, Rothschild SI, Scheel AH, Scheffler M, Schmalz P, Smit EF, Limburg M, Provencio M, Karachaliou N, Merkelbach-Bruse S, Hellmich M, Nogova L, Büttner R, Rosell R, Wolf J. Michels S, et al. Among authors: abdulla dsy. J Thorac Oncol. 2019 Jul;14(7):1266-1276. doi: 10.1016/j.jtho.2019.03.020. Epub 2019 Apr 9. J Thorac Oncol. 2019. PMID: 30978502 Free article. Clinical Trial.
Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations.
Scheffler M, Holzem A, Kron A, Nogova L, Ihle MA, von Levetzow C, Fassunke J, Wömpner C, Bitter E, Koleczko S, Abdulla DSY, Michels S, Fischer R, Riedel R, Weber JP, Westphal T, Gerigk U, Kern J, Kaminsky B, Randerath W, Kambartel KO, Merkelbach-Bruse S, Büttner R, Wolf J. Scheffler M, et al. Among authors: abdulla dsy. Lung Cancer. 2020 Jun;144:40-48. doi: 10.1016/j.lungcan.2020.04.020. Epub 2020 Apr 24. Lung Cancer. 2020. PMID: 32361034
Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment.
Nogova L, Mattonet C, Scheffler M, Taubert M, Gardizi M, Sos ML, Michels S, Fischer RN, Limburg M, Abdulla DSY, Persigehl T, Kobe C, Merkelbach-Bruse S, Franklin J, Backes H, Schnell R, Behringer D, Kaminsky B, Eichstaedt M, Stelzer C, Kinzig M, Sörgel F, Tian Y, Junge L, Suleiman AA, Frechen S, Rokitta D, Ouyang D, Fuhr U, Buettner R, Wolf J. Nogova L, et al. Among authors: abdulla dsy. Cancer Med. 2020 Jul;9(14):4991-5007. doi: 10.1002/cam4.3131. Epub 2020 May 21. Cancer Med. 2020. PMID: 32436621 Free PMC article.
Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma.
Riedel R, Michels S, Heydt C, Siemanowski J, Kobe C, Bunck A, Schäfer S, Fischer RN, Scheffler M, Abdulla DSY, Nogová L, Koleczko S, Merkelbach-Bruse S, Büttner R, Wolf J. Riedel R, et al. Among authors: abdulla dsy. Lung Cancer. 2019 Jul;133:20-22. doi: 10.1016/j.lungcan.2019.05.006. Epub 2019 May 6. Lung Cancer. 2019. PMID: 31200822
Treatment Monitoring of Immunotherapy and Targeted Therapy Using 18F-FET PET in Patients with Melanoma and Lung Cancer Brain Metastases: Initial Experiences.
Galldiks N, Abdulla DSY, Scheffler M, Wolpert F, Werner JM, Hüllner M, Stoffels G, Schweinsberg V, Schlaak M, Kreuzberg N, Landsberg J, Lohmann P, Ceccon G, Baues C, Trommer M, Celik E, Ruge MI, Kocher M, Marnitz S, Fink GR, Tonn JC, Weller M, Langen KJ, Wolf J, Mauch C. Galldiks N, et al. Among authors: abdulla dsy. J Nucl Med. 2021 Apr;62(4):464-470. doi: 10.2967/jnumed.120.248278. Epub 2020 Sep 4. J Nucl Med. 2021. PMID: 32887757
Monitoring Treatment Response to Erlotinib in EGFR-mutated Non-small-cell Lung Cancer Brain Metastases Using Serial O-(2-[18F]fluoroethyl)-L-tyrosine PET.
Abdulla DSY, Scheffler M, Brandes V, Ruge M, Kunze S, Merkelbach-Bruse S, Nogova L, Michels S, Fischer R, Riedel R, Büttner R, Persigehl T, Grau S, Galldiks N, Drzezga A, Kobe C, Wolf J. Abdulla DSY, et al. Clin Lung Cancer. 2019 Mar;20(2):e148-e151. doi: 10.1016/j.cllc.2018.10.011. Epub 2018 Nov 5. Clin Lung Cancer. 2019. PMID: 30528316 Free article. No abstract available.